AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE) - In May 2025, the Company presented initial safety and exploratory efficacy data from the first treated patient ...

(RTTNews) - Elekta AB Ser. B (EKTA-B.ST) announced that the U.S. Food and Drug Administration has granted 510 (k) clearance for its Leksell Gamma Knife radiosurgery system to treat refractory ...

ATLANTA - Elekta (EKTA-B.ST) today announced that it has received U.S. Food and Drug Administration (FDA) 510 (k) clearance to include refractory, intractable mesial temporal lobe epilepsy (MTLE ...

This is a study of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE). It is designed to investigate the Safety, Tolerability, and Efficacy of AMT-260 in Adults with ...

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE) ...

Neurona’s lead product candidate, NRTX-1001, comprising GABAergic interneurons, is currently being studied for safety and efficacy in two ongoing open label multicenter Phase 1/2 trials: NCT05135091 ...

About Refractory Mesial Temporal Lobe Epilepsy Temporal lobe epilepsy is a chronic neurologic disorder and is the most common form of focal epilepsy with more than 600,000 individuals suffering from ...

News GlobeNewswire uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) ...

TMCnet News uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) [May 29, 2025] ...

Investors are cautioned that any forward-looking statements, including updates regarding the future development of gene therapy candidates, including AMT-260 for drug-resistant mesial temporal lobe ...

Neurona has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.